The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
M. W. Jones
No relevant relationships to disclose
C. Zhang
No relevant relationships to disclose
K. R. Oettel
No relevant relationships to disclose
J. H. Blank
No relevant relationships to disclose
E. G. Robinson
No relevant relationships to disclose
H. G. Ahuja
No relevant relationships to disclose
R. J. Kirschling
No relevant relationships to disclose
P. H. Johnson
No relevant relationships to disclose
M. S. Huie
No relevant relationships to disclose
J. Kolesar
No relevant relationships to disclose
M. B. Wims
No relevant relationships to disclose
H. Hernan
No relevant relationships to disclose
T. C. Campbell
No relevant relationships to disclose
A. M. Traynor
No relevant relationships to disclose
T. Hoang
No relevant relationships to disclose